Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism

BACKGROUND: Pioglitazone is a promising therapeutic method for nonalcoholic fatty liver disease (NAFLD) patients with or without type 2 diabetes. However, there is remarkable variability in treatment response. We analyzed our previous randomized controlled trial to examine the effects of gender and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hongmei, Wu, Weiyun, Chang, Xinxia, Xia, Mingfeng, Ma, Sicheng, Wang, Liu, Gao, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784274/
https://www.ncbi.nlm.nih.gov/pubmed/33397443
http://dx.doi.org/10.1186/s13293-020-00344-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784274/
https://www.ncbi.nlm.nih.gov/pubmed/33397443
http://dx.doi.org/10.1186/s13293-020-00344-1

Ejemplares similares